Back to School: How biopharma can reboot drug development. Access exclusive analysis here

K-Rationalizing Vectibix use

Amgen Inc. recently convinced EMEA to reverse a negative opinion on Vectibix panitumumab based in part on biomarker data from a Phase III trial that showed how to focus use of the drug in patients for whom it works. For the same reason, the data ultimately may help U.S. sales of the drug, which have been sluggish. The key in both regions will be getting a diagnostic on the market.

AMGN confirmed that efficacy of the anti-EGFR antibody was confined to the subset of metastatic colorectal cancer patients with wild-type K-Ras (KRAS) gene expression. Its

Read the full 946 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE